AR091724A1 - Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica - Google Patents

Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica

Info

Publication number
AR091724A1
AR091724A1 ARP130102454A AR091724A1 AR 091724 A1 AR091724 A1 AR 091724A1 AR P130102454 A ARP130102454 A AR P130102454A AR 091724 A1 AR091724 A1 AR 091724A1
Authority
AR
Argentina
Prior art keywords
fampridine
laquinimod
multiple sclerosis
treatment
combination
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Kaye Joel
Tarcic Nora
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of AR091724A1 publication Critical patent/AR091724A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP130102454 2012-07-12 2013-07-10 Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica AR091724A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261670758P 2012-07-12 2012-07-12

Publications (1)

Publication Number Publication Date
AR091724A1 true AR091724A1 (es) 2015-02-25

Family

ID=49914160

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102454 AR091724A1 (es) 2012-07-12 2013-07-10 Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica

Country Status (17)

Country Link
US (2) US20140017226A1 (enExample)
EP (1) EP2872217A4 (enExample)
JP (1) JP2015522077A (enExample)
KR (1) KR20150038072A (enExample)
CN (1) CN104582793A (enExample)
AR (1) AR091724A1 (enExample)
AU (1) AU2013290181A1 (enExample)
BR (1) BR112015000616A2 (enExample)
CA (1) CA2873229A1 (enExample)
EA (1) EA201590191A1 (enExample)
HK (1) HK1209672A1 (enExample)
IL (1) IL236230A0 (enExample)
MX (1) MX2015000485A (enExample)
PY (1) PY1330684A (enExample)
TW (1) TW201408300A (enExample)
UY (1) UY34896A (enExample)
WO (1) WO2014011827A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013116657A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
MX2014009889A (es) 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
EA201590788A1 (ru) 2012-11-07 2015-12-30 Тева Фармасьютикал Индастриз Лтд. Аминные соли лахинимода
JP2016514162A (ja) 2013-03-14 2016-05-19 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドナトリウムの結晶およびその製造のための改善された方法
HK1231413A1 (zh) 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德
GB2540163A (en) * 2015-07-07 2017-01-11 Univ London Queen Mary Combination therapy for treating multiple sclerosis
WO2022150349A1 (en) * 2021-01-06 2022-07-14 The Penn State Research Foundation Methods and materials for treating bone loss

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726339D0 (en) * 1997-12-13 1998-02-11 Zeneca Ltd Human-derived tissue-specific potassium channel
US20090082471A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
ES2329327B1 (es) * 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.
CN101827522A (zh) * 2008-09-10 2010-09-08 阿索尔达治疗股份有限公司 持续释放氨基吡啶组合物的使用方法
NZ597378A (en) * 2009-06-19 2014-08-29 Teva Pharma Treatment of multiple sclerosis with laquinimod
SG11201401330YA (en) * 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod

Also Published As

Publication number Publication date
EA201590191A1 (ru) 2015-06-30
IL236230A0 (en) 2015-01-29
CA2873229A1 (en) 2014-01-16
US20160235735A1 (en) 2016-08-18
PY1330684A (es) 2016-06-01
HK1209672A1 (en) 2016-04-08
KR20150038072A (ko) 2015-04-08
WO2014011827A1 (en) 2014-01-16
EP2872217A1 (en) 2015-05-20
TW201408300A (zh) 2014-03-01
CN104582793A (zh) 2015-04-29
AU2013290181A1 (en) 2015-02-26
JP2015522077A (ja) 2015-08-03
MX2015000485A (es) 2015-04-08
BR112015000616A2 (pt) 2017-06-27
US20140017226A1 (en) 2014-01-16
EP2872217A4 (en) 2016-03-16
UY34896A (es) 2014-02-28

Similar Documents

Publication Publication Date Title
AR090491A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
HK1199820A1 (en) Treatment of multiple sclerosis with combination of laquinimod and fingolimod
MX2014001050A (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero.
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
MX2024010140A (es) Nuevos metodos.
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
RU2018145985A (ru) Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
MX379286B (es) INHIBIDORES DE PCSK9 PARA USARSE EN EL TRATAMIENTO DE PACIENTES CON HIPERCOLESTEROLEMIA FAMILIAR HETEROCIGOTA (HFHe).
BR112015001847A8 (pt) Composições e tratamento para doenças e distúrbios nos olhos
PY1330684A (es) Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
BR112015007095A8 (pt) derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados, composição farmacêutica compreendendoos e uso dos referidos derivados
WO2013038200A3 (en) Neurodevelopmental disorders
MX2016001177A (es) Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina.
MX385725B (es) Composición farmacéutica que comprende sumatriptán para tratamiento de migraña.
UY35748A (es) Terapia combinada con laquinimod para el tratamiento de la esclerosis múltiple
WO2014170820A3 (en) A pharmaceutical combination for treating tuberculosis
PH12014500252A1 (en) Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate
AR088093A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y acetato de glatiramer
AR103764A1 (es) Pridopidina como mejoradora de la función cognitiva y en el tratamiento de la enfermedad de alzheimer
HK1227691A1 (zh) 利用拉喹莫德和特立氟胺的组合来治疗多发性硬化症

Legal Events

Date Code Title Description
FB Suspension of granting procedure